Division of Pulmonary, Critical Care and Sleep Medicine, University of Florida - Jacksonville, 655 West 8th Street, C54 Clinical Center, 7th Floor, Jacksonville, FL, 32209, USA
Auto-generated profile, based on publicly available information
Michael D. Schweitzer
Division of Pulmonary, Critical Care and Sleep Medicine, University of Florida - Jacksonville, 655 West 8th Street, C54 Clinical Center, 7th Floor, Jacksonville, FL, 32209, USA
Bronchiectasis is a chronic disease characterized by irreversible airway dilation, persistent inflammation, and recurrent infections. Its global prevalence has risen significantly, now surpassing 1400 cases per 100,000 in certain regions, likely due to increased awareness over the last several decades. Bronchiectasis exhibits wide heterogeneity in etiology and clinical phenotype. Advances in imaging, microbiology, and biomarker profiling have refined diagnostic accuracy and revealed distinct endotypes, including those characterized by neutrophilic and eosinophilic inflammation. Innovations in therapy, ranging from airway clearance and inhaled antibiotics to emerging biologics and neutrophil-targeted therapies, underscore a shift toward individualized treatment. In this review, we provide a comprehensive and up-to-date discussion of the pathophysiological mechanisms, etiologies, and evolving management strategies in bronchiectasis.
Background: Mounier‐Kuhn syndrome (MKS), or tracheobronchomegaly, is a rare disorder characterized by dilation of the trachea and main bronchi due to atrophy of elastic and smooth muscle fibers. It is associated with recurrent respiratory infections, bronchiectasis, and airway collapse. Although radiological diagnosis is well established, clinical recognition remains delayed in many cases due to the disease′s rarity and nonspecific presentation. Case Presentation: We present a 56‐year‐old male with a known history of MKS who presented with pleuritic chest pain, productive cough, and constitutional symptoms. Computed tomography (CT) scans of the chest showed significant tracheobronchomegaly with posterior tracheal diverticulum and cystic bronchiectasis. Laboratory evaluation was unremarkable, and infectious and autoimmune workups were negative. The patient was treated conservatively with pulmonary hygiene, bronchodilators, and symptom‐targeted therapy, leading to gradual improvement. Discussion: This case dives into a noninfectious symptomatic flare of MKS, expanding the clinical understanding of its complications. We explore the pathophysiology of pleuritic pain in this setting and review diagnostic delays, bronchiectasis‐related morbidity, and therapeutic strategies. Advances in interventional pulmonology, including airway stenting and tracheobronchoplasty, offer promising outcomes in selected patients. Early identification, structured imaging assessment, and a multidisciplinary approach are key in managing this complex syndrome.